An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia

An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia is an investigation grounded in clinical expertise in movement disorders and botulinum toxin therapeutics. 

Cervical dystonia is a focal movement disorder characterized by involuntary muscle contractions of the neck, producing abnormal postures and often significant pain and functional impairment. Botulinum toxin injections have become a central symptomatic therapy for cervical dystonia; this study specifically examines the safety and efficacy of repeated administrations of ABP-450, a formulation of prabotulinumtoxinA, across multiple centers in an open-label format. The open-label, multicenter design allows for collection of safety and efficacy data in a real-world, clinically representative setting where repeat dosing reflects routine therapeutic practice. As an open-label study, participants and investigators are aware of treatment allocation, which can facilitate pragmatic assessment of tolerability, repeat-administration effects, and longitudinal outcomes under conditions approximating typical clinical care. 

The principal goals of the study are to systematically document adverse events, monitor tolerability with repeated intramuscular administrations, and evaluate clinical efficacy measures relevant to symptom control, functional improvement, and patient-reported outcomes. Collecting such data over repeated treatment cycles can inform clinicians regarding sustained benefit, waning effects, neutralizing antibody considerations, and safety signals that may emerge only with multiple exposures.

Findings from this study are expected to contribute to the evidence base guiding use of prabotulinumtoxinA in cervical dystonia, clarifying its role among available botulinum toxin therapies and supporting informed decision-making by clinicians and patients.